Corrigendum: PD-1/PD-L1 immune checkpoint therapy demonstrates favorable safety profile in patients with autoimmune and cholestatic liver disease

Front Immunol. 2024 Jan 24:15:1369747. doi: 10.3389/fimmu.2024.1369747. eCollection 2024.

Abstract

[This corrects the article DOI: 10.3389/fimmu.2023.1326078.].

Keywords: PD-1/PD-L1 immune checkpoint inhibitors; autoimmune disease (AID); autoimmune hepatitis (AIH); autoimmune liver diseases (AILD); immune checkpoint inhibitors (ICI); immune related adverse effects (irAEs); primary biliary cholangitis (PBC); primary sclerosing cholangites (PSC).

Publication types

  • Published Erratum